Fibromyalgia

NeuroMetrix Announces Peer-Reviewed Publication of a Randomized Controlled Trial of its Wearable Neurostimulation Technology for Treatment of Fibromyalgia

Monday, July 26, 2021 - 2:00pm

WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research.

Key Points: 
  • WOBURN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced a publication titled Effects of Wearable Transcutaneous Electrical Nerve Stimulation on Fibromyalgia: A Randomized Controlled Trial" in the Journal of Pain Research.
  • Note: The use of Quell for fibromyalgia is investigational and has not been cleared or approved by the U.S. Food and Drug Administration (FDA).
  • Fibromyalgia is a common form of chronic pain that is also accompanied by fatigue, sleep, cognitive and mood disturbances.
  • Quell is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain.

Tryp Therapeutics Announces Plans for Phase 2a Clinical Trial for Fibromyalgia with the University of Michigan

Wednesday, July 21, 2021 - 12:00pm

The study is expected to be the world's first Phase 2a clinical trial evaluating the efficacy of psilocybin and psychotherapy to treat fibromyalgia

Key Points: 
  • The open-label Phase 2a clinical trial will evaluate the efficacy of TRYP-8802, an oral formulation of synthetic psilocybin, in tandem with psychotherapy for treating fibromyalgia.
  • The Principal Investigator for the trial will be Kevin Boehnke, Ph.D., Research Investigator, University of Michigan Department of Anesthesiology.
  • Tryp expects to submit the Investigational New Drug (IND) application to the FDA for the Phase 2a clinical trial in 3Q 2021.
  • The company has announced upcoming Phase 2a clinical trials with the University of Michigan and the University of Florida to evaluate its drug products for fibromyalgia and eating disorders, respectively.

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

Wednesday, July 21, 2021 - 1:45pm

Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.

Key Points: 
  • Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.
  • Tryp will be collaborating with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School, a leading center in chronic pain research.
  • The upcoming Phase 2a trial is believed to be the world's first Phase 2 trial utilizing psilocybin for a chronic pain indication.
  • The clinical trial seeks to apply the neuroplasticity benefits of psilocybin to address the source of pain signals in fibromyalgia patients.

Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness

Wednesday, July 21, 2021 - 1:45pm

NEW YORK, July 21, 2021 /PRNewswire/ -- The early 1970s saw psychedelics and psilocybin products made illegal in the US in the war on drugs. Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4%  and 20.6% of the adult population respectively. As psychedelics gain more recognition, companies such as Tryp Therapeutics (CSE:TRYP) (OTCQB:TRYPF), Seelos Therapeutics (NASDAQ:SEEL), Numinus Wellness Inc. (TSXV:NUMI) (OTC:LKYSF), Mind Medicine (MindMed) (NASDAQ:MNMD) (NEO:MMED), and Mydecine Innovations Group Inc. (NEO:MYCO) (OTCPK:MYCOF) are engaging in research initiatives to develop psychedelic-assisted therapies for different mental illnesses and chronic pain conditions.

Key Points: 
  • Decades later, new research indicates the medical potential of psilocybin and psychedelics in the treatment of chronic pain and mental illness, which affect approximately 20.4% and 20.6% of the adult population respectively.
  • Tryp will be collaborating with the Chronic Pain & Fatigue Research Center in the Department of Anesthesiology at the University of Michigan Medical School, a leading center in chronic pain research.
  • The upcoming Phase 2a trial is believed to be the world's first Phase 2 trial utilizing psilocybin for a chronic pain indication.
  • The clinical trial seeks to apply the neuroplasticity benefits of psilocybin to address the source of pain signals in fibromyalgia patients.

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Fibromyalgia with its Wearable Neurostimulation Technology

Tuesday, July 20, 2021 - 2:00pm

Although several drugs are FDA approved for managing fibromyalgia pain, there is an unmet need for safe and effective non-pharmacological treatments.

Key Points: 
  • Although several drugs are FDA approved for managing fibromyalgia pain, there is an unmet need for safe and effective non-pharmacological treatments.
  • Under the program, the FDA will provide NeuroMetrix with priority review and interactive communication regarding device development, through to commercialization.
  • The data submitted by NeuroMetrix in support of the Breakthrough Designation included results from a double-blind, randomized, sham-controlled trial (NCT03714425).
  • Quell is a wearable neurostimulation device indicated for treatment of lower extremity chronic pain.

Cannabinoid Receptor-1 is a Major Focus of Drug Developers in the Fibromyalgia Competitive Landscape, 2021 Market Report - ResearchAndMarkets.com

Tuesday, July 6, 2021 - 9:12am

The "Fibromyalgia - Competitive Landscape in 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Fibromyalgia - Competitive Landscape in 2021" report has been added to ResearchAndMarkets.com's offering.
  • This reports provides a data-driven overview of the current and future competitive landscape in fibromyalgia therapeutics.
  • In fibromyalgia Cannabinoid receptor-1 is a major focus of drug developers.
  • Fibromyalgia - Competitive Landscape in 2021 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Independence from Pain: World Institute of Pain Spotlights Advancements Helping Free Patients from Chronic Pain

Thursday, July 1, 2021 - 2:05pm

On this Independence Day, the World Institute of Pain highlights the growing field of research and treatment options which are helping Americans live free from chronic pain.

Key Points: 
  • On this Independence Day, the World Institute of Pain highlights the growing field of research and treatment options which are helping Americans live free from chronic pain.
  • Dr. Peter Staats, President of the World Institute of Pain, says, Chronic pain has historically been viewed through a behavioral lens as though it were purely in patients heads.
  • While patients understand that chronic pain is not imaginary, physicians can also do their part to free patients from the stigma associated with it by employing a holistic approach that considers three modulators of chronic pain: cognition, behavior and biology.
  • There are many types of chronic pain, such as migraine and cluster headaches, chronic back pain, cancer pain, fibromyalgia, and most recently, COVID-19 long-haul symptoms.

Aviv Clinics open in Dubai, offers Hyperbaric Therapy for Fibromyalgia Treatment

Wednesday, June 30, 2021 - 11:40am

DUBAI, UAE, June 30, 2021 /PRNewswire/ -- Aviv Clinics , a state-of-the-art Hyperbaric Chamber Clinic, has opened its services in Dubai recently.

Key Points: 
  • DUBAI, UAE, June 30, 2021 /PRNewswire/ -- Aviv Clinics , a state-of-the-art Hyperbaric Chamber Clinic, has opened its services in Dubai recently.
  • The clinic plans to offer Hyperbaric Therapy and combat the Fibromyalgia Syndrome (FMS) condition in the country.
  • Although not hereditary, Fibromyalgia still develops at a frequent pace from environmental stimuli such as diseases, significant injury, or psychosocial circumstances.
  • To know more about Aviv Clinics and their new Hyperbaric Chamber Therapy treatment, visit their website at https://aviv-clinics.ae/ .

Aviv Clinics open in Dubai, offers Hyperbaric Therapy for Fibromyalgia Treatment

Wednesday, June 30, 2021 - 11:38am

DUBAI, UAE, June 30, 2021 /PRNewswire/ -- Aviv Clinics , a state-of-the-art Hyperbaric Chamber Clinic, has opened its services in Dubai recently.

Key Points: 
  • DUBAI, UAE, June 30, 2021 /PRNewswire/ -- Aviv Clinics , a state-of-the-art Hyperbaric Chamber Clinic, has opened its services in Dubai recently.
  • The clinic plans to offer Hyperbaric Therapy and combat the Fibromyalgia Syndrome (FMS) condition in the country.
  • Although not hereditary, Fibromyalgia still develops at a frequent pace from environmental stimuli such as diseases, significant injury, or psychosocial circumstances.
  • To know more about Aviv Clinics and their new Hyperbaric Chamber Therapy treatment, visit their website at https://aviv-clinics.ae/ .

Tonix Pharmaceuticals Announces Program to Develop TNX-102 SL for the Treatment of Long COVID Syndrome, also Known as Post-Acute Sequelae of COVID-19 (PASC)

Monday, June 21, 2021 - 12:00pm

Although most people recover from COVID-19 within weeks of the acute illness, a substantial portion develop a chronic syndrome called Long COVID, or PASC.

Key Points: 
  • Although most people recover from COVID-19 within weeks of the acute illness, a substantial portion develop a chronic syndrome called Long COVID, or PASC.
  • Most Long COVID patients who have been studied appear to have cleared the SARS-CoV-2 virus from their systems.
  • By improving sleep quality, we believe TNX-102 SL may improve the sleep disturbance of Long COVID and potentially also improve other symptoms of Long COVID.
  • For example, TNX-102 SL showed activity in addressing persistent pain, sleep disturbance and fatigue in our fibromyalgia Phase 3 study.